VBI Vaccines Inc. Stock News

VBI Vaccines Inc. said Wednesday the first clinical data from a Phase I trial of a pan-coronavirus vaccine candidate produced broad and durable protection against variants of concern.

VBI Vaccines (NASDAQ: VBIV ) stock is taking a beating on Thursday after the pharmaceutical company announced two stock offerings. VBI Vaccines announced both a public stock offering and a registered

VBI Vaccines, Inc. (VBIV) came out with a quarterly loss of $2.43 per share versus the Zacks Consensus Estimate of a loss of $2.27. This compares to loss of $2.40 per share a year ago.

VBI Vaccines (VBIV) will focus on its HBV vaccine product and advancing its HBV immunotherapeutic candidate. It will also reduce the workforce by 30-35% and initiate a 1-for-30 reverse stock split.

VBI Vaccines Inc. VBIV, -0.96% said Tuesday it is planning to focus its efforts on hepatitis B, as part of a reorganization that will see it cut operating costs and headcount by 30% to 35% and conduct

VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of -14.29% and 85.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

VBI Vaccines (VBIV) enters into a partnership with Agenus to conduct a study evaluating the former's VBI-1901 in combination with the latter's balstilimab for primary glioblastoma.

VBI Vaccines has not been immune to sell-off with their share price shrinking by roughly 75% over the past year despite the company making significant headway both clinically and commercially. VBIV is

The stock price of VBI Vaccines (VBIV) fell by 10.72% after hours in the most recent trading session. This is why.

Healthcare has become a bona fide stock picker's market this year.

Check these three biotech penny stocks out for your watchlist right now The post 3 Biotech Penny Stocks That Climbed in After-Hours Trading appeared first on Penny Stocks to Buy, Picks, News and Infor

VBI Vaccines recently reported updated data from their VBI-1901 candidate in recurrent Glioblastoma. The company publicized the median overall survival and 18-month overall survival data are outperfor

VBI Vaccines press release (VBIV): FY GAAP EPS of $0.27 beats by $0.54.Revenue of $0.63M (-40.6% Y/Y) misses by $0.17M.As of December 31, 2021 cash, cash equivalents…

VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of 0% and 40.88%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

VBI Vaccines (VBIV) is trading ~3% higher in the premarket Friday after the commercial stage vaccine maker announced that an expert panel of the European Medicines Agency ((EMA)) issued…